Aatur Singhi, MD PhD

Pancreatic/Gastrointestinal Pathologist.
T/RT ≠ medical advice

[Aatur Singhi, MD PhD @PancPathologist]

A tweetorial on our study (https://t.co/OCqCRJEMdx). But, first a case: Young female w/ a 1.9 cm incidental pancreatic cyst. No concerning features, but KRAS, TP53 and SMAD4 mutations on molecular testing. Surgical resection: #IPMN w/ a small #PancreaticCancer. #Pathology #GIPath

[Nieves Martinez Lago MD PhD @DraMartinezLago]

😂🧬 @OncoThor’s treatment algorithm is going international!

@JHernando3 brings it to #GETNE26 🇪🇸

💊 CAPTEM, PRRT, everolimus, cabozantinib…

🧭 So many options in pNETs… good thing we have a therapeutic GPS! 😂

[Syed A. Ahmad @SyedAAhmad5]

Outlook and Microsoft being down really sucks. Can’t get anything done.

Time to watch sports. I guess

[Sinchita Roy MD PhD @Sinchita_Roy]

@cytopathology #AMP2026

[Sinchita Roy MD PhD @Sinchita_Roy]

Thank you @AMPath for hosting the @cytopathology Companion Society session at #AMP2026 It was an honor moderating this fantastic #MolCytoPath session
@PancPathologist @HeymannJonas @pathnerd @Molecular_MD @aakasharmand @baj917

[Yale Cancer Center @YaleCancer]

A Yale study led by @YangLiu_Yale presents a spatially-resolved epigenomic atlas of NF-PanNETs across tumor grades, providing new insights into epigenetic heterogeneity and tumor-stroma interactions & a foundation for future functional and clinical investigation.
https://t.co/acOLlk3oes
@SmilowCancer @YaleGICancers @iScience_CP @PamelaKunzMD @Cecchini_OncMD @yalepathology @NeurologyYale

[Eric Topol @EricTopol]

Notable: Researchers from 50 institutions collaborate to find a biomarker that has the potential to detect ovarian cancer very early, even pre-malignant
A cancer not detected by the Galleri test.
An extracellular vesicle long non-coding RNA
@NatureMedicine
https://t.co/mUHNWs6m1U
https://t.co/AypMcJ9WXO

[UPMC Hillman Cancer Center @UPMCHillmanCC]

Happening live at #SITC2026 a robust discussion on spatial biology & immune responses. Dr Tullia Bruno (@BcellBruno) leads the program in Halls BC North Building 300 level at the Phoenix CC. @UPMCnews @PittHealthSci @PittDeptofMed

[UPMC Hillman Cancer Center @UPMCHillmanCC]

If you're making plans for Thursday's start of #SITC2026 & want the latest info on bioinformatics, big data & AI, check out this pre-conference program with @RiyueSunnyBao. @UPMCNews @PittHealthSci @DBMI_Pitt

[UPMC Hillman Cancer Center @UPMCHillmanCC]

Need tips on writing grants? Join Dr. Abby Overacre @OveracreLab & learn about Low-preliminary Data Grants (DP5, R21, High Risk/High Reward Grants) & Dr. Greg Delgoffe @DelgoffeLab on Funding Your Research Through Industry Collaborations #SITC2026. @UPMCnews @PittHealthSci

[Nature Cancer @NatureCancer]

🌟Online now
@ednacukierman, Igor Astsaturov & co uncover that CAFs fuel pancreatic tumor growth and immune suppression by transferring membrane lipids to cancer cells through trogocytosis.
https://t.co/oST61d6t1N

[Sinchita Roy MD PhD @Sinchita_Roy]

Heading to #AMP2026 and wondering what to do before the meeting starts?
Join us at Special Programs Day for @cytopathology session, Nov 10 at 5 pm
Included with your meeting registration but you have to sign up
Maximizing #CytoPath for #MolPath 🧬
#supernatants #NGS @AMPath

[Eric Topol @EricTopol]

Th distinct features of colon cancer in the young at single-nucleus resolution, both unfavorable and potentially helpful for understanding why this is on the rise @NatureMedicine
https://t.co/aOUDUNV80U

[Giovanni Marchegiani @Gio_Marchegiani]

🔙 to anatomy! Why transection site 🧈 🔪 matters in developing POPF…

🏗️ Architecture of pancreatic ductal network shows regional variability

💦 POPF for atypical resection site might eventually develop

Anatomy 🫶 surgery always!

https://t.co/k4ZMz6MVey

[Arndt Vogel @ArndtVogel]

RASolute 302 ph3 study: Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated mPDAC
#ESMO26 #ESMOAmbassadors
👉 mOS: 13.2 vs 6.7 mo
👉ORR improved in all RAS mutations
👉PFS & OS: small subgroups, favourable for all
🧐great data, consistent benefits for all pts
@myESMO @ASCO

[Anirban Maitra @Aiims1742]

Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26
https://t.co/iaYLkWsnsl
Reduced toxicity data is particularly important as a lower Daraxonrasib dose can be used.

[Anirban Maitra @Aiims1742]

Early data on VS-7375, @VerastemOncolog KRASG12D inhibitor in 2nd line and beyond #PancreaticCancer
50% ORR in 2nd line, 35% in 3rd/4th line
6mo OS of 80%
Proceeding with Phase 3 randomized trial in 1st line pancreatic (VS-7375 +EGFRi v VS-7375 + chemo)
https://t.co/DQbMMWKkOx

[Arndt Vogel @ArndtVogel]

Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
@Annals_Oncology
https://t.co/q8W867xpij
👉get the latest updates
👉Biomarker testing (e.g. HER2, MSI, CLDN18.2, PD-L1) key
@myESMO @ASCO

[Anirban Maitra @Aiims1742]

“It’s been a journey” Shroff told @NBCNews. “I’ve spent my entire life trying to eradicate cancer, primarily pancreatic cancer, but also liver cancers.”
https://t.co/qGmDCVg30K
An homage to Rachna Shroff, including thoughts from her family. Please read, share & honor her memory.

[Diane M. Simeone, MD @MadameSurgeon]

Published today in Nature Genetics, our lab research team reveals how pancreatic cancer cells shift between subtypes and adapt within tumors. These insights could help advance more effective treatments for patients.

https://t.co/72SlKBcJA1

[Maxim Artyomov @maxim_artyomov]

Out today in Immunity! Our pan-atlas of human immune aging: 12.4 million PBMCs from 2,609 people across 8 global cohorts (including new 188 people cohort from UK).
https://t.co/hYbe2k3XEi
We map shared aging patterns onto 59 key immune populations and link the balance of GZMK+ and GZMB+ CD8 effector memory T cells to health trajectories; show differences in RTEs and Th2s with sex etc; ethnicity associated features.

https://t.co/AHmFVQVfM6

How it came to be:
in 2023 we published first hierarchically annotatied atlas of human immune aging in PBMC - 166 people, 55 populations, key changes revealed - CD8 naives, KLRC2/NKG2C+ CD8 memory going down, GZMK+ CD8 T cells and Th2 and Tc2 type 2 memory cells going up! (Terekhova et al, Immunity 2023)

in 2024 we added major phenotypes within naive cells - SOX4+ RTE cells and their CD38 marker going down. (Bohacova et al, Immunity 2024)

In 2025-26 more atlases published with their own annotations making impossible to leverage power of data..

Now we provide unique in its power and consistency resource - 2600 people across ages, sexes, races, continents etc. All annotated in sync and analyzed for what aging looks like globally!